March 5, 2018 / 9:18 PM / 7 months ago

BRIEF-Glycomimetics Announces Design Of Phase 3 Clinical Trial For GMI-1271

March 5 (Reuters) - Glycomimetics Inc:

* GLYCOMIMETICS ANNOUNCES DESIGN OF PHASE 3 CLINICAL TRIAL FOR GMI-1271 IN RELAPSED/REFRACTORY AML

* GLYCOMIMETICS INC - PRIMARY ENDPOINT FOR SINGLE PIVOTAL CLINICAL TRIAL WILL BE OVERALL SURVIVAL

* GLYCOMIMETICS INC - MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020

* GLYCOMIMETICS INC - IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below